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Background: The effect of commonly used oral contraceptives (OCs) on blood pressure is still unclear. The aim of
this study was to examine the relationship between OCs use and blood pressure and the prevalence of
hypertension in a population-based sample of Korean women.
Methods: A cross-sectional study was conducted using data from 3356 participants aged 35–55 years collected in
the 2007–2009 Korea National Health and Nutrition Examination Surveys. OC use and demographic characteristics
were obtained from participants using a questionnaire, and blood pressure was measured with a mercury
sphygmomanometer.
Results: Longer duration of OC use was positively associated with increasing levels of systolic blood pressure and
diastolic blood pressure (p for trend <0.001). After adjusting for covariates, the odds ratio (OR) of hypertension was
significantly increased in longer-term (>24 months) OC users (OR 1.96; 95% confidence interval (CI) 1.03–3.73)
compared with those who had never used OCs. Additionally, use of OCs >24 months was associated with increased
odds of prehypertension (adjusted OR 2.23; 95% CI 1.28–3.90) and hypertension or prehypertension (adjusted OR
2.13; 95% CI 1.37–3.32).
Conclusion: This study found a statistically significant association between OC use and blood pressure or
hypertension among Korean women.
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Hypertension is one of the most prevalent and etiologically
significant risk factors for cardiovascular disease [1].
Although various approaches have been applied in the
general population for the prevention, treatment, and
control of high blood pressure, hypertension remains a
major public health concern [2]. Among women, more
than 25% of the world adult population is hypertensive,
and an estimated 23.9% of Korean women aged 30 years or
older are hypertensive [3,4]. Furthermore, the prevalence of
hypertension is predicted to increase more in women than
in men [5]. Hypertension contributes to more excess deaths
in women than does any other preventable cardiovascular* Correspondence: kimkisok@kmu.ac.kr
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reproduction in any medium, provided the ordisease risk factor. It is considered a complex-trait disease
resulting from interactions between genetic and environ-
mental factors, including oral contraceptive (OC) use [6,7].
OCs are an important and widely accepted contraceptive
modality worldwide [8]. In Korea, most OCs contain
20–40 mg ethinyl estradiol as the estrogen component
in addition to a progestin component. Although the
incidence of OC-induced adverse effects is thought to be
much lower now with the newer generation of prepara-
tions, which contain lower doses of estradiol, OC use is still
known to contribute to adverse health effects, including
hypertension [7,9,10].
Until now, several epidemiological studies have indicated
that exposure to OCs may have an effect on blood pressure.
OCs has been reported to cause alterations in systolic blood
pressure (SBP), diastolic blood pressure (DBP), and the
prevalence of hypertension in various study designs withl Ltd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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findings from epidemiological studies of the association
between OCs and hypertension have been less consistent;
according to the population studied, different levels of SBP
and DBP have been reported following the administration
of OCs. In particular, relatively little information is available
about the effect of commonly used OCs containing both
estrogen and progestin on blood pressure or the prevalence
of hypertension in Korean women.
Alteration of blood pressure profiles may represent an
important and potentially etiological component in the
pathogenesis of many disorders, including cardiovascular
disease, stroke, and renal disease [13]; thus, it is important
to examine the association between OC use and hyperten-
sion. Thus, the purpose of this study was to investigate
this association in Korean women using data from the
2007–2009 Korea National Health and Nutrition Examin-
ation Survey (KNHANES), a nationally representative
survey conducted in the Republic of Korea.
Methods
Study population
This study was based on data from the 2007–2009
KNHANES, provided by the Korea Centers for Disease
Control and Prevention. The sample for KNHANES was
selected using a stratified, multistage, cluster-sampling
design with proportional allocation based on the National
Census Registry. Detailed information on survey design
and sampling procedures has been reported elsewhere
[14]. In total, 600 sampling units were randomly sampled,
and 3641 women aged 35–55 years who had no missing
response on the questionnaire were included. Of the 3641
participants, 285 participants were excluded because
they were taking drugs for hormone replacement therapy
(n = 272) or were pregnant (n = 13). Thus, the final analysis
included 3356 subjects.
Data collection
KNHANES included well-established questions to deter-
mine demographic and socioeconomic characteristics of
the subjects. These included questions on age, gender,
education level, income, physical exercise, smoking habits,
and alcohol consumption. Height and weight were
measured with the participants wearing light clothing
and no shoes. Body mass index (BMI) was then calcu-
lated as weight (in kg) divided by the square of height
(in m). Then, subjects were categorized as underweight
(BMI < 18.5), normal (18.5 ≤ BMI < 23.0), overweight
(23.0 ≤ BMI < 25.0), or obese (BMI ≥ 25.0), according to the
World Health Organization (WHO) definitions for Asian
populations [15]. Information on OC use, including num-
ber of months of use, was obtained by a self-administered
questionnaire, and blood pressure was measured while
subjects were in a sitting position after a 5-min period ofcomfortable, seated rest. Blood pressure was measured on
three occasions with a mercury sphygmomanometer on
the right arm, and the second and third measurements
were averaged.
The study protocol was approved by the Korean Ministry
of Health and Welfare and was conducted in accordance
with the Ethical Principles for Medical Research Involving
Human Subjects, as defined by the Helsinki Declaration.
All study participants provided written informed consent.
Variable definitions
Hypertensive status was sorted into three categories:
normotensive, prehypertensive, and hypertensive. Normo-
tension was defined as not taking an antihypertensive
medication and having a SBP of <120 mmHg and DBP
of <80 mmHg. Prehypertension was defined as not taking
antihypertensive medication and having a SBP of 120–
139 mmHg and/or DBP of 80–89 mmHg. Hypertension
was defined as SBP ≥140 mmHg and/or DBP ≥90 mmHg
or taking medication for hypertension [16]. As a covariate,
education level was categorized as less than a high school
diploma, high school diploma, and college or higher.
Alcohol consumption was assessed by questioning the
subjects about their drinking behavior during the month
before the interview. The subjects were asked about
the average frequency and amount of alcoholic beverage
intake. The average amount and number of alcoholic
beverages consumed were converted into the amount of
pure alcohol (ethanol) consumed per day.
Statistical analyses
The frequency and percentage or mean and standard error
(SE), as appropriate, were calculated for demographic char-
acteristics to describe the sample population according
to categories of duration of OC use. Logistic regression
models were used to estimate the odds ratio (OR) and 95%
confidence intervals (CIs) for prehypertension (vs. normo-
tension) and hypertension status (vs. normotension) among
participants who consumed OCs compared with the refer-
ence group (those who never used OCs). The presence of
a linear trend was evaluated by defining a linear contrast
in each of the linear and logistic regression models. All
statistical analyses were conducted using SAS software
(ver. 9.2; SAS Institute, Cary, NC, USA). Statistical analyses
accounted for the survey design, and appropriate proce-
dures in SAS such as surveymeans, surveyfreq, and
surveylogistic were used with weighted data.
Results
This study included 3356 women aged 35–55 years; their
demographic characteristics are shown in Table 1. The
mean age and mean BMI of the study participants were
44.0 years and 23.5, respectively, and OCs were used by
512 (15.3%) participants. The basic characteristics and













< High school 936 27.9
High school 1561 46.5
> High school 859 25.6















Park and Kim BMC Women's Health 2013, 13:39 Page 3 of 7
http://www.biomedcentral.com/1472-6874/13/39outcomes of the study population, sorted by duration of
OC use, are presented in Table 2. As duration of OC use
increased, participants were more likely to have a low
education level (p for trend <0.001). Additionally,
duration of OC use was correlated positively with age
(p for trend = 0.002), regular exercise (p for trend = 0.041),
amount of cigarette smoking (p for trend <0.001), and
alcohol consumption (p for trend = 0.044). Average house-
hold income was negatively associated with increased OC
use (p for trend <0.001).
The overall mean SBP and DBP of the study population
were 111.7 and 74.2 mmHg, respectively, and the trends
for the weighted mean SBP and DBP were significantly
related to increased OC use (Table 3). The weighted mean
SBP and DBP were higher among participants using OCs
for a longer period of time (p for trend <0.001). Accord-
ingly, a significant dose–response trend existed between
duration of OC use and hypertension prevalence (p for
trend = 0.001), with 18.1% of the population havinghypertension in the group that never used OCs compared
with 34.8% in the group that had used OCs for over
24 months. Additionally, the duration of OC use was sig-
nificantly associated with the prevalence of prehypertension
(p for trend = 0.001) and the prevalence of hypertension
or prehypertension (p for trend <0.001).
Table 4 shows the ORs for the association of hyper-
tension and prehypertension with duration of OC use.
The adjusted ORs for hypertension were positively cor-
related with increased duration of OC use (p for trend =
0.012). Compared with those who never used OCs, the
adjusted ORs were 0.99 (95% CI 0.65–1.51) among
those who used OCs for 0 to <12 months, 1.22 (95% CI
0.75–1.99) among those used OCs for 12–24 months,
and 1.96 (95% CI 1.03–3.73) among those used OCs
for >24 months. The trends in adjusted ORs with longer
duration of OC use were also positive for prehypertension
(p for trend = 0.010) and for hypertension or prehyper-
tension (p for trend = 0.005). Adjusted ORs for prehyper-
tension among the same OC use groups were 1.00 (95%
CI 0.68–1.48), 0.86 (95% CI 0.56–1.34), and 2.23 (95% CI
1.28–3.90), respectively, compared with the reference group,
and adjusted ORs for hypertension or prehypertension
were 1.02 (95% CI 0.72–1.43), 0.97 (95% CI 0.68–1.38),
and 2.13 (95% CI 1.37–3.32), respectively (Figure 1).
Discussion
OCs containing estrogen and progestin constitute a
widely used means of contraception. Currently used
third-generation OCs were designed to minimize adverse
effects, including unfavorable effects on the cardiovascular
system [17]. Since their introduction, a number of studies
have confirmed that their effects on blood pressure are
indeed less than those observed with first- and second-
generation OCs [18,19]. However, controversy persists
about the possible risks of OC use, including cardiovas-
cular disease, partially through the promotion of adverse
changes in blood pressure [20].
In the present nationwide cross-sectional study among
Korean women aged 35–55 years, the duration of OC
use was positively associated with SBP and DBP levels.
SBP and DBP among those who had used OCs >24 months
were higher than among those who had never used them
by 5.8 and 3.6 mmHg, respectively. Similar to the results
of this study, most studies have reported a steady increase
in SBP and DBP among users of third-generation OCs
containing estrogen and progestin. However, the magni-
tude of the increase varies among populations and also
with the duration of OC use. Case–control studies using
24-h ambulatory BP monitoring indicated a higher SBP
and DBP in OC users than in non-users of about 7.6–8.6/
1.8–5.8 mmHg [21,22]. Also, a prospective study of
approximately 18 000 US women reported an increase in
SBP and DBP by 5–6 mmHg and 1–2 mmHg, respectively,
Table 2 Weighted demographic characteristics by duration of oral contraceptive use
Characteristics










Age (years), mean (SE) 43.9 (0.1) 43.5 (0.3) 44.9 (0.5) 45.5 (0.7) 0.002
BMI, mean (SE) 23.4 (0.1) 23.3 (0.2) 23.8 (0.4) 23.7 (0.4) 0.161
Education (%) <0.001
< High school 24.9 35.2 48.5 34.6
High school 48.5 42.9 37.3 58.1
> High school 26.6 21.9 14.2 7.3
Average household income (US$/month), mean (SE) 2712.3 (59.5) 2626.2 (103.1) 2278.6 (137.8) 2005.3 (143.2) <0.001
Regular exercise (%) 54.6 53.8 56.9 65.9 0.041
Smoking (cigarettes/day), mean (SE) 0.39 (0.05) 0.79 (0.17) 1.11 (0.42) 1.64 (0.49) <0.001
Alcohol drinking (g/day), mean (SE) 3.14 (0.17) 3.41 (0.51) 5.14 (0.82) 4.55 (1.06) 0.044
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WHO reported that women using OCs showed increased
SBP and DBP, by 3.6–5.0 mmHg and 1.9–2.7 mmHg,
respectively, compared with those using an intrauterine
device [25]. A similar finding has been reported in
German women; OC users had, on average, significantly
higher levels of SBP and DBP than non-users by ~3.6
and ~1.4 mmHg, respectively [26]. However, SBP and
DBP among current OC users were higher than those
among never users by only 0.7/0.4 mmHg in a prospective
cohort study in the United States [12]; furthermore, SBP
increased by only 2 mmHg and no change was found in
DBP in British women between the ages of 18 and 30 years
[27]. A possible explanation for these differing effects of
OCs on blood pressure among studies may be differences
in OC formulations and treatment regimens as well as the
age and race/ethnicity factors of participants. Thus, it is
important to examine the effect of OCs on blood pressure
in a Korean population exposed to third-generation OCs
for different periods of time.
In this study, hypertension, prehypertension, or
prehypertension + hypertension were about twofold more
common in women taking OCs for more than 2 yearsTable 3 Weighted distributions of blood pressure-related var
Characteristics Overall Never
(n = 2844)
Blood pressure (mm Hg),
mean (95% CI)*
Systolic 111.7 (110.7–112.6) 111.4 (110.4–112.4)




Prehypertensive or Hypertensive 36.0 35.4
*Excludes participants who reported being currently treated for hypertension.than in women not taking OCs. However, no significant
increase was observed among women who had used OC
use for less than 2 years in the odds of hypertension,
prehypertension, or prehypertension + hypertension. Al-
though the cumulative time of OC use shown to produce
an increased odds of hypertension varies by study,
long-term effects of OC use on hypertension have been
confirmed in many studies [7,11,12]. Prehypertension
is a precursor of clinical hypertension and is associated
with an increased risk of cardiovascular disease [28,29].
Given that the prehypertension, as well as hypertension, is
an important risk factor for cardiovascular morbidity and
mortality [5,30], data from this study suggest that taking
OCs for more than 2 years may be a risk factor in the
development of cardiovascular disease, leading to an
increased risk of premature death in Korean women.
Although the detailed biological mechanism of the
hypertensive risk due to exogenous estrogen and/or pro-
gestin remains to be determined, estrogen and progester-
one are known to regulate many intracellular signal
transduction and cellular functions [17,31]. Estrogens
acting on estrogen receptors α and β are recognized as
important regulators of intracellular signaling cascadesiables by duration of oral contraceptive use
Duration of oral contraceptive use
p






111.1 (109.2–112.9) 114.8 (111.0–118.7) 117.2 (113.4–121.0) <0.001
74.2 (72.9–75.4) 76.9 (74.5–79.4) 77.8 (75.1–80.5) <0.001
13.9 21.3 22.8 0.006
21.0 19.2 34.3 0.017
34.9 40.5 57.2 <0.001
Table 4 Odds ratios and 95% confidence intervals for hypertension and prehypertension by duration of oral
contraceptive use
Duration of oral contraceptive use p for
linear trendNever (n = 2844) <0– < 12 mo (n = 304) 12–24 mo (n = 132) >24 mo (n = 76)
Hypertension
Crude 1.00 (reference) 0.97 (0.65–1.43) 1.63 (1.05–2.52) 2.42 (1.43–4.09) <0.001
Adjusted* 1.00 (reference) 0.99 (0.65–1.51) 1.22 (0.75–1.99) 1.96 (1.03–3.73) 0.012
Prehypertension
Crude 1.00 (reference) 0.99 (0.68–1.43) 0.99 (0.64–1.53) 2.46 (1.44–4.19) 0.001
Adjusted* 1.00 (reference) 1.00 (0.68–1.48) 0.86 (0.56–1.34) 2.23 (1.28–3.90) 0.010
Prehypertension or Hypertension
Crude 1.00 (reference) 0.98 (0.71–1.34) 1.24 (0.90–1.73) 2.44 (1.63–3.66) <0.001
Adjusted* 1.00 (reference) 1.02 (0.72–1.43) 0.97 (0.68–1.38) 2.13 (1.37–3.32) 0.005
*Adjusted for age, BMI, education, income, exercise, cigarette smoking, and alcohol consumption.
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regulate vascular tone, mediated by nitric oxide, prosta-
cyclin, angiotensin, and the sympathetic nervous system
[33-35]. Moreover, the type and dose of progestin in OCs
can influence blood pressure [36,37]. For example, it has
been reported that progesterone-induced increases in
aminopeptidase P may contribute to the development of
OC-induced hypertension in susceptible women [38].Figure 1 Adjusted odds ratios for hypertension and prehypertensionThe present study has several limitations. As a result of
the cross-sectional design, the results only demonstrated
associations and could not be used to determine causality.
Additionally, self-reporting of drinking and smoking
patterns and of OC use may lead to misclassification
and measurement error [39]. Although this study included
adjustment for many potential confounding factors, the re-
sults may have been confounded by unmeasured covariates,by oral contraceptive use.
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Furthermore, although genetic and enzymatic factors
are important in the metabolism of OCs and in the
homeostatic regulation of blood pressure, the results
of this study could not determine how the association
of OCs with blood pressure may be affected by these
factors. Despite these limitations, this study had several
major strengths. To our knowledge, this is the first reported
study to assess the association between duration of OC use
and hypertension or prehypertension in Korean women
using nationally representative data. Another strength is
that this study analyzed not only hypertension status but
also prehypertension following OC use. Future studies
investigating the mechanisms underlying the relationship
between OCs and blood pressure and any racial/ethnic
differences among populations are required to confirm
and extend the results of this study.
Conclusion
In this population-based study of Korean women aged
35–55 years, long-term use of OCs was associated with
increased SBP and DBP. Additionally, odds of hyper-
tension or prehypertension was significantly increased
among women using OCs for more than 2 years com-
pared with non-users. Although controlled studies to
investigate causal relationships between OC use and blood
pressure are needed, the present results suggest significant
associations between long-term use of OCs and increased
hypertension.
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